This document is a publication of a European patent application (EP4648772A1) by the European Patent Office (EPO). The patent, assigned to Poolbeg Pharma (UK) Limited, relates to P38 map kinase inhibitors for use in alleviating cancer immunotherapy-associated cytokine release syndrome. The publication date is March 18, 2026.

As this is a patent publication, it does not impose direct regulatory obligations or compliance deadlines on regulated entities. However, it signifies potential advancements in drug development for cancer treatment and related side effects. Companies involved in pharmaceutical research and development, particularly in oncology and immunotherapy, should be aware of this patent filing as it may impact future intellectual property landscapes and competitive strategies.